Luc St-Onge
Corporate Officer/Principal bij Licensing Executives Society
Profiel
Luc St-Onge is a Member of Licensing Executives Society and Pharma-Lizenz-Club Deutschland.
He previously worked as Director-Diabetes Program at DeveloGen AG, Chief Business Officer at Affectis Pharmaceuticals AG, and Research Scientist at Max Planck Gesellschaft zur Förderung der Wissenschaften eV.
He holds a doctorate degree from the University of Sherbrooke.
Actieve functies van Luc St-Onge
Bedrijven | Functie | Begin |
---|---|---|
Licensing Executives Society | Corporate Officer/Principal | - |
Pharma-Lizenz-Club Deutschland | Corporate Officer/Principal | - |
Eerdere bekende functies van Luc St-Onge
Bedrijven | Functie | Einde |
---|---|---|
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Corporate Officer/Principal | - |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Corporate Officer/Principal | - |
Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Corporate Officer/Principal | - |
Opleiding van Luc St-Onge
University of Sherbrooke | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
Affectis Pharmaceuticals AG
Affectis Pharmaceuticals AG Pharmaceuticals: MajorHealth Technology Affectis Pharmaceuticals AG discovers and develops drugs for the treatment of neurodegenerative and neuroinflammatory diseases. Its products in pipeline include AFC-5128, P2X7 Compounds, AFC-5278 and AFC-08. The company was founded in January 2004 by Florian Holsboer, Wolfgang Wurst and Herbert Stadler and is headquartered in Dortmund, Germany. | Health Technology |
DeveloGen AG
DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Licensing Executives Society | |
Pharma-Lizenz-Club Deutschland | |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Miscellaneous |